<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873687</url>
  </required_header>
  <id_info>
    <org_study_id>Card-202103.01</org_study_id>
    <nct_id>NCT04873687</nct_id>
  </id_info>
  <brief_title>Effectiveness of ECP Therapy in Stable Angina Pectoris Patients</brief_title>
  <official_title>Effectiveness of External Counter Pulsation (ECP) Therapy in Stable Angina Pectoris Patients; a Proof of Principal Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitas Padjadjaran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitas Padjadjaran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      External Counterpulsation (ECP) is a non-invasive therapy using pressured cuff that is&#xD;
      performed on patients with refractory stable angina pectoris to relieve symptoms and increase&#xD;
      quality of life. In Indonesia, waiting time for getting coronary artery bypass grafting&#xD;
      (CABG) procedure for revascularization treatment in stable angina pectoris patients is way&#xD;
      longer than international recommendation which correlates with increase morbidity and&#xD;
      mortality during the waiting time. Utilization of ECP for such patients who wait for CABG&#xD;
      procedure is still unclear. The investigator aim to evaluate efficacy of addition of ECP&#xD;
      compared with medical therapy alone for this population. The efficacy is evaluated using&#xD;
      measurement from echocardiography result, treadmill test result, and clinical outcome. if&#xD;
      applicable, examination of myocardial perfusion using nuclear examination will also be&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Waiting time for elective CABG procedure in Indonesia is usually longer than six weeks, way&#xD;
      longer than the European society of cardiology recommendation. During the waiting time,&#xD;
      patients still complain of having troubling chest pain and at risk from 1.7% mortality even&#xD;
      after optimal medical therapy. ECP is a non-invasive therapy using a pressured cuff performed&#xD;
      on patients that have been utilized in refractory angina pectoris patients to relieve&#xD;
      symptoms, increase the quality of life, and decrease future major adverse cardiac events&#xD;
      (MACE).&#xD;
&#xD;
      This study is proof of principal clinical trial to evaluate the efficacy of addition ECP&#xD;
      therapy after optimal medical therapy for stable angina pectoris patients waiting for CABG in&#xD;
      Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Eligible patients will be informed&#xD;
      about the study and randomized to the intervention arm. Patients in the experimental arm will&#xD;
      undergo ECP therapy consisting of 36 sessions, each session @1 hour/day, six days a week with&#xD;
      an initial pressure of 300mmHg. No intervention will be given to patients in the control arm.&#xD;
&#xD;
      The primary and secondary endpoint is the change in variables measured before and after the&#xD;
      intervention is fully implemented. The primary endpoint variables are global longitudinal&#xD;
      strain (GLS), Left ventricular ejection fraction (LVEF, Time to ST-Segment depression,&#xD;
      duration of treadmill test, the Canadian cardiovascular society (CCS) score, the Seattle&#xD;
      angina questionnaire (SAQ) score, and frequency of nitroglycerin use. The secondary endpoint&#xD;
      variable will be myocardial perfusion score measured as Summed Rest Score, Summed Stress&#xD;
      Score, and Summed Difference Score and incidence of MACE. This change will then be compared&#xD;
      between the intervention experimental arm and control arm.&#xD;
&#xD;
      Safety oversight by a Data and Safety Monitoring Board (DSMB) will be conducted by&#xD;
      independent parties. Internal Data Monitoring Committee (DMC) will be established to oversee&#xD;
      the study, focused on data quality. Quality control (QC) procedures will be implemented&#xD;
      beginning with the data entry system. Data QC checks that will be run on the database will be&#xD;
      automatically generated weekly, and any quality issues identified will be reviewed by the DMC&#xD;
      a plan put in place for resolution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The intervention will be administered to eligible stable angina pectoris patients Dr. Hasan Sadikin General Hospital in a randomized manner neither of experiment or control group.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor and study statistician will not be aware of intervention assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Longitudinal Strain (GLS)</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>GLS is a parameter captured through transthoracic echocardiography. GLS was calculated as the mean peak longitudinal systolic strain of all the LV segments, consistent with American Society of Echocardiography (ASE) guidelines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>LVEF is a parameter captured through transthoracic echocardiography. LVEF was calculated by Simpson biplane method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Time to mm ST-segment Depression</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Time to induce significant ST-segment Depression using treadmill exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Duration of Treadmill Test</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Maximally tolerated time of treadmill exercise test using Bruce protocol or modified bruce protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CCS score</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Degree of presenting chest pain symptoms using the Canadian cardiovascular society (CCS) class score. CCS class score ranging from 1 (mild) to 4 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Seattle Angina Questionnaire (SAQ) Score</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Quality of life based on The Seattle Angina Questionnaire measurement. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Nitroglycerin Use</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Frequency of sublingual nitroglycerin use per week to alleviate chest pain symptoms.Change in frequency of sublingual nitroglycerin use was defined as the total number reported during the last one weeks at baseline and last one week before intervention completed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Summed Rest Score (SRS)</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Summed Rest Score is part of myocardial perfusion parameters of SPECT myocardial perfusion defects examination. The score are accumulated from 17 polar map segment. each segment scored. the extent and severity of perfusion deficits while rest ranging from 0 to 4 with higher score mean worse clinical apperance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Summed Stress Score (SSS)</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Summed Stress Score is part of myocardial perfusion parameters of SPECT myocardial perfusion defects examination. The score are accumulated from 17 polar map segment. each segment scored. the extent and severity of perfusion deficits while stress ranging from 0 to 4 with higher score mean worse clinical apperance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Summed Difference Score (SDS)</measure>
    <time_frame>At baseline and week 7 (post intervention)</time_frame>
    <description>Summed Difference Score is part of myocardial perfusion parameters of SPECT myocardial perfusion defects examination. SDS can be calculated by subtracting the SRS from the SSS (SDS = SSS - SRS). This measure is used to describe the degree to which the deficit/ischemia is reversible. An SDS score of 0-1 indicates no ischemia; 2-4 points indicate mild ischemia; 5-6 points indicate moderate ischemia; while 7 or more points indicate severe ischemia,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of incidence of Major adverse cardiac event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Counterpulsation</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Eligible stable angina pectoris patients in the control arm will receive no intervention therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>External Counter Pulsation (ECP) therapy</intervention_name>
    <description>ECP therapy consist of 36 session, each session @1 hour/day, six days a week with initial pressure of 300mmHg</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Diagnosed with stable angina pectoris&#xD;
&#xD;
          -  Anatomic vessel disease (VD) lesion with 2VD/3VD&#xD;
&#xD;
          -  Indicated CABG and in waiting list of CABG procedure&#xD;
&#xD;
          -  Not planned to urgent CABG&#xD;
&#xD;
          -  Minimum optimal medical therapy within 1 week&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congestive Heart Failure&#xD;
&#xD;
          -  LVEF &lt;35%&#xD;
&#xD;
          -  Unprotected left main stenosis &gt;50%&#xD;
&#xD;
          -  Blood pressure &gt;180/110mmHg&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Acute Heart Failure&#xD;
&#xD;
          -  Severe aorta regurgitation&#xD;
&#xD;
          -  Malignant arrhythmia&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Premature ventricular complex&#xD;
&#xD;
          -  Peripheral occlusive artery disease&#xD;
&#xD;
          -  Phlebitis&#xD;
&#xD;
          -  Deep vein thrombosis&#xD;
&#xD;
          -  Hemorrhagic diathesis&#xD;
&#xD;
          -  Severe chronic kidney disease&#xD;
&#xD;
          -  Aortic aneurysm&#xD;
&#xD;
          -  Abdominal aneurysm&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Registered as other clinical study participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad R Akbar, MD, FIHA.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Padjadjaran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad R Akbar, MD, FIHA.</last_name>
    <phone>+6281221040265</phone>
    <email>m.r.akbar@unpad.ac.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Badai B Tiksnadi, MD, FIHA.</last_name>
    <phone>+628112237277</phone>
    <email>badai.bhatara.tiksnadi@unpad.ac.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Hasan Sadikin General Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Badai B Tiksnadi, MD, FIHA</last_name>
      <phone>+62112237277</phone>
      <email>badai.bhatara.tiksnadi@unpad.ac.id</email>
    </contact>
    <investigator>
      <last_name>Badai B Tiksnadi, MD, FIHA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999 Jun;33(7):1833-40.</citation>
    <PMID>10362181</PMID>
  </reference>
  <reference>
    <citation>Wu E, Desta L, Broström A, Mårtensson J. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. J Cardiovasc Nurs. 2020 Jul/Aug;35(4):375-385. doi: 10.1097/JCN.0000000000000638.</citation>
    <PMID>31929322</PMID>
  </reference>
  <reference>
    <citation>Subramanian R, Nayar S, Meyyappan C, Ganesh N, Chandrakasu A, Nayar PG. Effect of Enhanced External Counter Pulsation Treatment on Aortic Blood Pressure, Arterial Stiffness and Ejection Fraction in Patients with Coronary Artery Disease. J Clin Diagn Res. 2016 Oct;10(10):OC30-OC34. Epub 2016 Oct 1.</citation>
    <PMID>27891374</PMID>
  </reference>
  <reference>
    <citation>Zhang C, Liu X, Wang X, Wang Q, Zhang Y, Ge Z. Efficacy of Enhanced External Counterpulsation in Patients With Chronic Refractory Angina on Canadian Cardiovascular Society (CCS) Angina Class: An Updated Meta-Analysis. Medicine (Baltimore). 2015 Nov;94(47):e2002. doi: 10.1097/MD.0000000000002002.</citation>
    <PMID>26632696</PMID>
  </reference>
  <reference>
    <citation>Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Kappetein AP, Kastrati A, Knuuti J, Kolh P, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Windecker S, Jüni P, Sousa-Uva M. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017 Aug 1;52(2):206-217. doi: 10.1093/ejcts/ezx115. Review.</citation>
    <PMID>28472484</PMID>
  </reference>
  <reference>
    <citation>Rampengan SH, Prihartono J, Siagian M, Immanuel S. The Effect of Enhanced External Counterpulsation Therapy and Improvement of Functional Capacity in Chronic Heart Failure patients: a Randomized Clinical Trial. Acta Med Indones. 2015 Oct;47(4):275-82.</citation>
    <PMID>26932695</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitas Padjadjaran</investigator_affiliation>
    <investigator_full_name>Badai Bhatara Tiksnadi</investigator_full_name>
    <investigator_title>Head of Cardiovascular Prevention and Rehabilitation Clinic Dr. Hasan Sadikin General Hospital</investigator_title>
  </responsible_party>
  <keyword>External Counterpulsation</keyword>
  <keyword>Stable Angina Pectoris</keyword>
  <keyword>Indicated CABG</keyword>
  <keyword>Global longitudinal strain</keyword>
  <keyword>Ischemic response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

